title: Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.
abstract: BACKGROUND
  Visceral leishmaniasis (VL) caused by an intracellular protozoan parasite Leishmania, is fatal in the absence of treatment. At present there are no effective vaccines against any form of leishmaniasis. Here, we evaluate the potency, efficacy and durability of DNA/DNA, DNA-prime/Protein-boost, and Protein/Protein based vaccination against VL in a susceptible murine model.
  
  
  RESULTS
  To compare the potency, efficacy, and durability of DNA, protein and heterologous prime-boost (HPB) vaccination against Leishmania donovani, major surface glycoprotein gp63 was cloned into mammalian expression vector pcDNA3.1 for DNA based vaccines. We demonstrated that gp63 DNA based vaccination induced immune responses and conferred protection against challenge infection. However, vaccination with HPB approach showed comparatively enhanced cellular and humoral responses than other regimens and elicited early mixed Th1/Th2 responses before infection. Moreover, challenge with parasites induced polarized Th1 responses with enhanced IFN-γ, IL-12, nitric oxide, IgG2a/IgG1 ratio and reduced IL-4 and IL-10 responses compared to other vaccination strategies. Although, vaccination with gp63 DNA either alone or mixed with CpG- ODN or heterologously prime-boosting with CpG- ODN showed comparable levels of protection at short-term protection study, DNA-prime/Protein-boost in presence of CpG significantly reduced hepatic and splenic parasite load by 10⁷ fold and 10¹⁰ fold respectively, in long-term study. The extent of protection, obtained in this study has till now not been achieved in long-term protection through HPB approach in susceptible BALB/c model against VL. Interestingly, the HPB regimen also showed marked reduction in the footpad swelling of BALB/c mice against Leishmania major infection.
  
  
  CONCLUSIONS
  HPB approach based on gp63 in association with CpG, resulted in robust cellular and humoral responses correlating with durable protection against L. donovani challenge till twelve weeks post-vaccination. These results emphasize the potential of DNA-prime/Protein-boost vaccination over DNA/DNA and Protein/Protein based vaccination in maintaining long-term immunity against intracellular pathogen like Leishmania.
authors.affiliation: Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Kolkata, India.
authors.forename: Saumyabrata
authors.initials: S
authors.lastname: Mazumder
authors.forename: Mithun
authors.initials: M
authors.lastname: Maji
authors.forename: Amrita
authors.initials: A
authors.lastname: Das
authors.forename: Nahid
authors.initials: N
authors.lastname: Ali
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000502:physiology; D016466:CHO Cells; D003001:Cloning, Molecular; D006224:Cricetinae; D003412:Cricetulus; D016054:DNA, Protozoan / Q000276:immunology* / Q000378:metabolism; D007893:Leishmania donovani / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D008647:Mesocricetus; D008666:Metalloendopeptidases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D016052:Protozoan Vaccines / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D016054:DNA, Protozoan; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D008666:Metalloendopeptidases; C055146:glycoprotein gp63, Leishmania